A National Registry on Chinese Patients With Cystic Fibrosis

Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians. Only a few Chinese CF patients have been described in literature, taking into account the large population of China. The main objectives of this study are to accurately evaluate the prevalence of CF, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pulmonary Function

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Location status: Recruiting

Location contact

XinLun Tian, M.D.

CONTACT

[email protected]

86-10-69155039

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informed consent.

Exclusion criteria

Patients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease

Treatment and study plan

Primary outcomes

Change in spirometry (FEV1 and FVC) of lymphangioleiomyomatosis patients.

Time frame: 10 years

Spirometry will be evaluated at baseline and through study completion, an average of 3 years.

Study contacts

Contact information is provided by the study sponsor or research team.

Xinlun Tian, M.D.

CONTACT

[email protected]

86-10-69155039

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Registry information

Official study title

A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Cystic Fibrosis (CF-CHINA)

Important dates

Study start: 2022
Primary completion: 2032
Study completion: 2032
First posted: Mar 21, 2022
Registry last updated: Mar 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting